Latigo Biotherapeutics secures $150M series B to advance non-opioid pain treatments

Thousands Oak, CA, March 17, 2025 (PRNewswire) -- Latigo Biotherapeutics, a clinical-stage biotechnology company, has successfully closed a $150 million Series B financing round, led by funds managed by Blue Owl Capital. The investment will facilitate the development of Latigo’s selective Nav1.8 inhibitors, including LTG-001 for acute pain and LTG-305 for chronic pain, both designed as non-opioid pain treatments. New and existing investors, including Deep Track Capital, Access Biotechnology, and Sanofi Ventures, reinforced their support for Latigo’s mission to create safer, non-addictive pain therapies. Additionally, Kevin Raidy, Senior Managing Director at Blue Owl Capital, has joined the company’s board of directors. CEO Nima Farzan emphasized the urgent need for innovation in pain management and highlighted the company's progress in clinical trials.

Read full article here.